On June 30, 2021 Again Life Italia S.r.l. ("ALI"), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited ("TannerLAC"), a subsidiary of Tanner Pharma Group and commercialization leader in Latin America, reported the signing of a business partnership agreement for Latin America (Press release, Tanner Pharma Group, JUN 30, 2021, View Source [SID1234584516]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With their global presence, ALI is dedicated to supporting cancer patients undergoing chemo and radiation therapy. Similarly, TannerLAC supports patients and biopharma companies by providing access to medicines in targeted markets.

Carolina Cortez, EVP of TannerLAC, commented, "We are very excited about the opportunity to work with Again Life Italia to improve the quality of life of patients in Latin America who experience side effects from chemo and radiation therapies."

Antonella Sardei, CEO of Again Life Italia, added, "Our partnership with TannerLAC is strategic to promote the products and the philosophy of Again Life Italia in Latin American countries and is in line with the company’s mission in supporting patients, especially those affected by side effects related to anticancer treatments, giving them the respect due to those who suffer."

The objective of the partnership is to leverage TannerLAC’s 18 years of experience to provide ALI’s innovative treatments to markets such as Argentina, Brazil, Chile, Colombia, Ecuador, Mexico and Peru.